Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.

Volz AK, Dingemanse J, Krause A, Lehr T.

Pharm Res. 2019 Dec 10;37(1):2. doi: 10.1007/s11095-019-2723-3.

PMID:
31823033
2.

Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences.

Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, Lehr T, Milligan P, Nock V, Ramusovic S, Riggs M, Schaller S, Schlender J, Schmidt S, Sevestre M, Sjögren E, Solodenko J, Staab A, Teutonico D.

CPT Pharmacometrics Syst Pharmacol. 2019 Oct 31. doi: 10.1002/psp4.12473. [Epub ahead of print] Review. No abstract available.

3.

Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration.

Wilman HR, Parisinos CA, Atabaki-Pasdar N, Kelly M, Thomas EL, Neubauer S; IMI DIRECT Consortium, Mahajan A, Hingorani AD, Patel RS, Hemingway H, Franks PW, Bell JD, Banerjee R, Yaghootkar H.

J Hepatol. 2019 Sep;71(3):594-602. doi: 10.1016/j.jhep.2019.05.032. Epub 2019 Jun 19.

4.
5.

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Moj D, Maas H, Schaeftlein A, Hanke N, Gómez-Mantilla JD, Lehr T.

Clin Pharmacokinet. 2019 Dec;58(12):1577-1593. doi: 10.1007/s40262-019-00776-y.

PMID:
31104266
6.

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.

Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T.

Pharmaceutics. 2019 Apr 1;11(4). pii: E152. doi: 10.3390/pharmaceutics11040152.

7.

Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.

Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T.

CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):296-307. doi: 10.1002/psp4.12397. Epub 2019 Mar 13.

8.

Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon.

Ramharter M, Schwab M, Mombo-Ngoma G, Zoleko Manego R, Akerey-Diop D, Basra A, Mackanga JR, Würbel H, Wojtyniak JG, Gonzalez R, Hofmann U, Geditz M, Matsiegui PB, Kremsner PG, Menendez C, Kerb R, Lehr T.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01113-18. doi: 10.1128/AAC.01113-18. Print 2019 Feb.

9.

A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors.

Balazki P, Schaller S, Eissing T, Lehr T.

CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):788-797. doi: 10.1002/psp4.12359. Epub 2018 Oct 22.

10.

PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.

Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):647-659. doi: 10.1002/psp4.12343. Epub 2018 Sep 7.

11.

Can toxicokinetics of (synthetic) cannabinoids in pigs after pulmonary administration be upscaled to humans by allometric techniques?

Schaefer N, Wojtyniak JG, Kroell AK, Koerbel C, Laschke MW, Lehr T, Menger MD, Maurer HH, Meyer MR, Schmidt PH.

Biochem Pharmacol. 2018 Sep;155:403-418. doi: 10.1016/j.bcp.2018.07.029. Epub 2018 Jul 24.

PMID:
30048626
12.

Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect.

Mulyukov Z, Weber S, Pigeolet E, Clemens A, Lehr T, Racine A.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):660-669. doi: 10.1002/psp4.12322. Epub 2018 Aug 15.

13.

Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.

Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J.

Hepatology. 2019 Jan;69(1):376-393. doi: 10.1002/hep.30190. Epub 2018 Dec 22.

14.

XplOit: An Ontology-Based Data Integration Platform Supporting the Development of Predictive Models for Personalized Medicine.

Weiler G, Schwarz U, Rauch J, Rohm K, Lehr T, Theobald S, Kiefer S, Götz K, Och K, Pfeifer N, Handl L, Smola S, Ihle M, Turki AT, Beelen DW, Rissland J, Bittenbring J, Graf N.

Stud Health Technol Inform. 2018;247:21-25.

PMID:
29677915
15.

Population nutrikinetics of green tea extract.

Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC.

PLoS One. 2018 Feb 21;13(2):e0193074. doi: 10.1371/journal.pone.0193074. eCollection 2018.

16.

How to disentangle psychobiological stress reactivity and recovery: A comparison of model-based and non-compartmental analyses of cortisol concentrations.

Miller R, Wojtyniak JG, Weckesser LJ, Alexander NC, Engert V, Lehr T.

Psychoneuroendocrinology. 2018 Apr;90:194-210. doi: 10.1016/j.psyneuen.2017.12.019. Epub 2017 Dec 29.

PMID:
29370954
17.

A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.

Hanke N, Teifel M, Moj D, Wojtyniak JG, Britz H, Aicher B, Sindermann H, Ammer N, Lehr T.

Cancer Chemother Pharmacol. 2018 Feb;81(2):291-304. doi: 10.1007/s00280-017-3495-2. Epub 2017 Dec 4.

PMID:
29204687
18.

The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine.

Schaefer N, Moj D, Lehr T, Schmidt PH, Ramsthaler F.

Int J Legal Med. 2018 Mar;132(2):415-424. doi: 10.1007/s00414-017-1754-8. Epub 2017 Dec 1.

PMID:
29196879
19.

A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T.

Cancer Chemother Pharmacol. 2017 Nov;80(5):1013-1026. doi: 10.1007/s00280-017-3447-x. Epub 2017 Oct 7.

20.

Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod.

Lott D, Lehr T, Dingemanse J, Krause A.

Clin Pharmacol Ther. 2018 Jun;103(6):1083-1092. doi: 10.1002/cpt.877. Epub 2017 Oct 27.

PMID:
28913826

Supplemental Content

Loading ...
Support Center